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a  b  s  t  r  a  c  t
Campylobacter  jejuni  is  one  of  the  leading  causes  of bacterial  diarrhea  worldwide  and  is  associated  with
a number  of  sequelae,  including  Guillain–Barre  Syndrome,  reactive  arthritis,  irritable  bowel  syndrome
and  growth  stunting/malnutrition.  Vaccine  development  against  C. jejuni  is complicated  by  its  antigenic
diversity,  a lack  of  small  animal  models,  and  a poor  understanding  of  the  bacterium’s  pathogenesis.
Vaccine  approaches  have  been  limited  to recombinant  proteins,  none  of  which  have  advanced  beyond
Phase  I  testing.  Genomic  analyses  have  revealed  the  presence  of a polysaccharide  capsule  on  C.  jejuni.
Given  the  success  of capsule-conjugate  vaccines  for other  mucosal  pathogens  of global  importance,  efforts
to evaluate  this  established  approach  for C.  jejuni  are  also  being  pursued.  A prototypical  capsule-conjugate
vaccine  has  demonstrated  efﬁcacy  against  diarrheal  disease  in non-human  primates  and  is currently  in
Phase I testing.  In addition  to proof  of concept  studies,  more  data  on  the  global  prevalence  of  capsular
types,  and  a better  understanding  of  the acute  and  chronic  consequences  of  C.  jejuni  are  needed  to  inform
investments  for a globally  relevant  vaccine.
© 2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC. Introduction
Campylobacter jejuni infection is the most common cause of
acterial gastroenteritis worldwide. The 2010 Global Burden of Dis-
ase study reported that Campylobacter accounts for the loss of
.5 million disability-adjusted life years (DALYs), more than other
lobally prevalent enteric (Shigella (7.1 million DALYs), enterotox-
genic Escherichia coli (ETEC) (6.8 million DALYs) or non-enteric
meningococcus (5.2 million DALYs, dengue (0.8 million DALYs))
athogens for which vaccines have already been or are being
eveloped [1]. In high-income countries, Campylobacter is a sig-
iﬁcant cause of traveler’s diarrhea and domestically associated
ood-borne infection [2–9]. The epidemiology of Campylobacter
s different in low- and middle-income countries, where infection
s considered almost universal in early childhood. Approximately
0–60% of children under the age of 5 will develop at least one
 Both authors are employees of the U.S. Government or military service members.
his work was prepared as part of ofﬁcial duties. Title 17 U.S.C. §105 provides that
Copyright protection under this title is not available for any work of the United
tates Government.” Title 17 U.S.C. §101 deﬁnes a U.S. Government work as a work
repared by a military service member or employee of the U.S. Government as part
f  that person’s ofﬁcial duties.
∗ Corresponding author. Tel.: 301 319 7686.
E-mail addresses: mark.s.riddle10.mil@mil.mil, markriddlemd@hotmail.com,
arkriddlemd@gmail.com (M.S. Riddle).
ttp://dx.doi.org/10.1016/j.vaccine.2016.02.080
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceBY  license  (http://creativecommons.org/licenses/by/3.0/).
symptomatic infection, usually within the ﬁrst year of life [10].
Furthermore, asymptomatic infections and prolonged carriage are
common. Reliable studies deﬁning disease burden in the devel-
oping world are challenging as the microaerophilic nature and
fastidious growth requirements of this pathogen make culture
diagnosis difﬁcult, resulting in an underestimate of the incidence.
The Global Enterics Multi-Center Study (GEMS), a prospective,
multi-center, case-control study of acute moderate-severe diarrhea
in children that used high-quality culture based methods of diag-
nosis found Campylobacter to be among the top 5 causes of acute
diarrhea in 2 to 5-year-old children living in Bangladesh, Pakistan or
India [11]. Other studies using culture independent (e.g., methods
not relying on culturing the organism) and quantitative diagnostics
have found increased burden of disease attribution to Campylobac-
ter [12]. Most recently, pathogen attribution assessments using
culture-independent methods from The Etiology, Risk Factors, and
Interactions of Enteric Infections and Malnutrition and the Conse-
quences for Child Health and Development Project (MAL-ED Study)
found Campylobacter spp. to be the third leading cause of diarrhea
among infants 0–11 months old and the leading cause in children
12–24 months old. This study included all severity diarrheal disease
among birth cohorts across 8 countries in the developing world
[13]. The differential ranking of pathogens in the GEMS and MAL-
ED studies are likely due to a combination of factors, including
different study designs (cohort vs. case-control) and performance
characteristics of diagnostics utilized (e.g., culture-based vs. culture
independent methodologies).
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Campylobacter species are widely distributed commensal
oonotic organisms found in many types of livestock and domes-
icated animals. They are often associated with food-borne
utbreaks, contaminated water and uncooked meats, particularly
oultry. The infection typically presents, after a brief incubation
eriod of 1–3 days, with acute watery diarrhea (sometimes bloody),
bdominal pain and fever. In low resource settings, the clinical fea-
ures may  also include vomiting and signs of volume depletion.
usceptible patients in these settings are often underweight and/or
alnourished. Volume resuscitation is the mainstay of therapy in
ll settings. Although antibiotics have demonstrated beneﬁt dur-
ng severe illness, they are generally not indicated and their use
ay  actually contribute to the growing problem of antimicrobial
esistance. Campylobacter infection is commonly self-limiting, but
as been shown to be an independent risk factor for a growing list
f chronic sequelae. The most severe is Guillain–Barré syndrome
GBS), an ascending paralysis of autoimmune origin considered to
e the leading cause of acute ﬂaccid paralysis worldwide. C. jejuni
s the most frequent pathogen associated with GBS [14]. As dis-
ase burden studies have relied on culture-based diagnostics, they
ave likely underestimated the attribution of Campylobacter infec-
ion to GBS. In addition to GBS, a number of studies have identiﬁed
ther chronic health effects of Campylobacter infection, including
ut not limited to stunting, microbiome changes, functional bowel
isorders and reactive arthropathies [15]. Most recently, a Peruvian
irth cohort study found that both symptomatic and asymptomatic
ampylobacter infections were associated with growth reductions
ver the 9 months following infection and that the magnitude of
rowth retardation was correlated with the severity of infection
16]. Despite these studies, there remains a need for more global
esearch on the burden of campylobacteriosis, as called for in a
oint publication by the WHO, the Food and Agriculture Organiza-
ion of the United Nations (FAO) and the World Organization for
nimal Health (OIE) [17]. Large longitudinal cohort studies, like
AL-ED, have responded to this call and promise to provide better
isease burden data (e.g., DALYs associated with acute and chronic
onsequences) in the coming years [18].
. Biological feasibility for vaccine development
Currently, there are no vaccines approved by any global reg-
latory authority to prevent Campylobacter-associated illness.
iological feasibility of a Campylobacter vaccine is supported by
ata from epidemiologic and human challenge studies. The epi-
emiology of Campylobacter infections in the developing world is
haracterized by falling incidence of clinical disease with increas-
ng age, particularly after 5 years of age when infections become
ostly asymptomatic [19,20]. These observations suggest acquired
rotection to infection over time and repeated exposures, In addi-
ion, human challenge studies have demonstrated that previously
nfected subjects can be protected from disease following chal-
enge with the homologous strain of bacteria [21,22]. Vaccine
trategies against C. jejuni are limited by an incomplete understand-
ng of its pathogenesis, protective epitopes, antigenic diversity,
s well as its association with post-infectious syndromes such
s reactive arthritis, IBS and GBS. Human challenge studies indi-
ate that although infected subjects are subsequently protected
rom disease after challenge, the bacteria succeed in coloniz-
ng and inducing local and intestinal antibody responses [21,22].
t is not known what degree of infection or illness increases
he risk of chronic sequelae or whether colonization alone is
tself a risk, but it highlights important considerations regarding
linically relevant endpoints: prevention of disease, prevention
f infection or prevention of colonization, or a combination
hereof.e 34 (2016) 2903–2906
3. General approaches to vaccine development for low- and
middle-income country markets
Most strains of C. jejuni produce lipo-oligosaccharides (LOS)
that contain N-acetyl neuraminic acid moieties that are struc-
tural mimics of human gangliosides. Antibodies directed against
these ‘molecular mimics’ can cross-react with human peripheral
nerves, the pathogenic basis of GBS. Therefore, whole cell oral vac-
cines, which might seem logical for an enteric pathogen, may  not
be the best approach for C. jejuni.  The concerns about GBS have
generated increasing interest in alternative approaches that will
avoid the use of bacterial molecules that mimic  those of humans.
Genomic research has revealed that C. jejuni expresses a polysac-
charide capsule (CPS) [23] and has given rise to efforts to develop
a CPS-conjugate vaccine, similar to those that have been licensed
for other encapsulated, mucosal pathogens. Although molecular
details are lacking, invasion of intestinal epithelial cells is an impor-
tant early step in pathogenesis, and the polysaccharide CPS appears
to be critical for this process [24], supporting the hypothesis that
anti-capsular antibodies will confer protection against C. jejuni dis-
ease [25]. Furthermore, there is no evidence that any CPS structures
feature ganglioside mimics, alleviating concerns of GBS and distin-
guishing it from approaches containing the LOS core structures.
Conjugate vaccines have been widely used for more than 25 years
and have been safe and highly successful in preventing disease
caused by a variety of encapsulated namely type B Hemophilus
inﬂuenzae, Neisseria meningiditis and Streptococcus pneumoniae. A
prototype, monovalent conjugate vaccine against C. jejuni has pro-
vided 100% protection against diarrheal disease in non-human
primates [25]. However, a similar challenge for Campylobacter vac-
cine development using this approach will be developing a safe,
immunogenic formulation that covers the most relevant capsule
types for the target population
Beyond a CPS-based approach, recombinant protein subunit
antigens are also being explored. A recombinant form of an ABC
transporter, PEB1 has recently been shown in pre-clinical stud-
ies to be immunogenic and protective in a non-diarrheal disease
mouse model [26]. Campylobacter ﬂagellin had also been studied
as a potentially effective immunogen, but it is heavily glycosylated
and the surface exposed glycosylations vary among strains. More-
over, a recombinant non-glycosylated form of C. jejuni ﬂagellin was
poorly immunogenic in Phase I trials. A better understanding of
pathogenesis and virulence factors is ﬁrst needed to advance sub-
unit protein products. While more high-quality data are needed,
it is clear that C. jejuni is widely distributed and causes signiﬁcant
global morbidity and mortality. Given the past performance of CPS
conjugate vaccines, it is conceivable that a highly immunogenic and
safe vaccine could be manufactured for use in all relevant markets.
An effective C. jejuni vaccine would beneﬁt children living in devel-
oping countries, but would also appeal to travelers. As previously
stated, efforts are needed to understand CPS type valency distribu-
tion in the developing world, and the attributable burden of acute
and chronic consequences of infection through better epidemiolog-
ical studies. With such data, a convincing case for a C. jejuni vaccine
in these target populations could be made. Furthermore, with the
potential of this vaccine having broader appeal to the developed
world (both in travelers and domestic settings), sufﬁcient markets
may  allow for tiered pricing as has been seen with other licensed
vaccines (e.g., rotavirus vaccines).
4. Technical and regulatory assessmentA capsule-conjugate vaccine approach against C. jejuni is
promising but several questions still need to be addressed. As men-
tioned previously, highly effective conjugate vaccines have been
M.S. Riddle, P. Guerry / Vaccin
Table  1
Development status of current vaccine candidates.
Candidate
name/identiﬁer



























































OC = Proof-of-concept trial.
eveloped for other mucosal pathogens, one of which, S. pneumo-
iae, has more capsular types (∼90) than C. jejuni (∼35) [27]. There
ave been numerous prevalence studies of capsule serotypes in the
eveloped world, but few studies from developing countries where
he disease incidence is higher (19). The complexity and cost of clas-
ical serotyping has limited its usefulness, but a recently developed
ultiplex PCR assay that determines capsule type offers the poten-
ial of a more rapid and affordable diagnostic [27]. Comparative
tudies have shown a strong correlation between the two  methods
nd are beginning to ascertain capsule-type distribution worldwide
28] (and Poly et al). Alternative vaccine approaches, such as recom-
inant protein subunits, have not yet demonstrated feasibility but
re likely to advance with improved understanding of campylobac-
er pathogenesis. Relevant non-human primate (NHP) disease and
uman challenge models will facilitate early evaluation of vaccine
andidates and lower risk during clinical development.
More research is needed on campylobacter–host interactions
nd epidemiology to identify adequate coverage of a capsule
onjugate or protein subunit vaccine. The identiﬁcation and char-
cterization of a correlate of protection is important and could be
nformed indirectly through seroepidemiological studies. Favor-
ble results from early phase clinical trials in adults from the
igh-income countries (e.g., travelers or other high-risk popula-
ions) would provide hope that such a vaccine might be effective
n low- and middle-income country populations. Using the capac-
ty built for rotavirus vaccine testing, there are sufﬁcient ﬁeld
ites, experience, and regulatory pathways to take a C. jejuni vac-
ine through safety studies and pivotal trials in low resource
ettings. While standardized and accepted endpoints exist for
otavirus-associated illness, acute gastroenteritis endpoints for ill-
ess associated with Campylobacter in the low resource settings
re needed. The incidence of C. jejuni disease is high enough to sup-
ort a trial with a feasible sample size. However, the formulation
f a C. jejuni vaccine needs to be considered carefully to ensure
cceptability and affordability in developing countries. In addi-
ion, the Expanded Programme on Immunization vaccine schedule
s already crowded, thus, integration of another vaccine into the
chedule will be complex.
. Status of vaccine R&D activities
C. jejuni vaccine candidates that have been or are in clini-
al development include killed whole cell, protein subunit and
apsule-conjugate products. A recombinant protein vaccine (ACE
93) was tested in a Phase II human challenge study but failed to
emonstrate protection. Killed whole-cell and recombinant ﬂag-
llin subunit vaccine constructs have also been advanced to human
linical trials but, again, both failed to demonstrate protection in a
hase II human challenge trial. Currently, the capsule-conjugate
accine is the leading vaccine under development, though a DNA
accine approach is in preclinical development (Table 1). A pro-
otypical monovalent CPS conjugate vaccine using CRM197 as the
rotein carrier has been evaluated in a number of preclinical studiese 34 (2016) 2903–2906 2905
and found to be highly immunogenic in mice, with signiﬁcantly ele-
vated anti-capsular IgG titers that persisted for >26 weeks (Guerry,
unpublished). Since mice do not develop diarrhea when orally chal-
lenged with C. jejuni, this vaccine candidate has been evaluated
for efﬁcacy against diarrheal disease in an NHP model (Aotus nan-
cymaae,  a new world owl  monkey species). In this model, 2.5 g
of conjugated polysaccharide was  given in three doses at 6-week
intervals by subcutaneous injection and provided 100% protection
from disease after infection with an orogastric challenge of the
homologous strain nine weeks after the last vaccine dose [29]. A
Phase I trial of this product is currently underway (clinicaltrials.gov,
NCT02067676). There is a human challenge model with a C. jejuni
strain that naturally lacks ganglioside mimicry in its LOS, which can
be used in proof of concept clinical trials [30]. Important to note,
while not currently being pursued as a vaccine candidate, in vitro
and pre-clinical studies suggest that antibodies elicited by cholera
toxin, but not enterotoxigenic E. coli heat-labile toxin, cross-react
with a single epitope of the major outer membrane protein of
Campylobacter and, thus, may  afford some level of cross protection
[31–34]. Lastly, several vaccine candidates are also in development
for the poultry industry, but are outside the scope of this review
and hence are not discussed.
6. Likelihood for ﬁnancing
Momentum has been building in both the public and pri-
vate sectors around research and development of new diarrheal
disease interventions, including rotavirus, cholera, typhoid, ETEC
and Shigella vaccines. Public funding for diarrheal diseases from
high-income country governments and multinational organiza-
tions has increased substantially. Global agencies have made
greater commitments to understanding diarrheal disease burden
and the impact of speciﬁc pathogens. Opportunities to lever-
age private markets for the public good through implementation
of tiered pricing schemes allow companies to achieve a return
on investment in proﬁtable markets (i.e., travelers and emerg-
ing economies), while providing products at lower cost in the
developing world. While industry funding would likely be able
to take a vaccine for the high-income country market, further
development in low- and middle-income country markets would
likely require funding and initiative from a range of sources,
including vaccine-manufacturing partners in potential target mar-
kets, national governments and global public health nonproﬁt
organizations. The emerging epidemiology and understanding of
campylobacter-attributable burden (both acute and chronic) in
both traveler and global populations, combined with promising
development in vaccines leads to the consideration of the pos-
sibility for a global vaccine against C. jejuni. The GAVI Alliance
has indicated an interest in enteric vaccines. A combination vac-
cine with one of the other major enteric pathogens (e.g., shigella
conjugate or typhoid conjugate) could enhance feasibility. Stud-
ies are also ongoing to evaluate conjugation of C. jejuni capsular
polysaccharides with subunit proteins from ETEC (Guerry et al.,
unpublished). A Campylobacter vaccine would likely have a dual
market (i.e., both developed and developing countries), providing
scale-up advantages for commercial development and global dis-
tribution.
Disclaimer
The views expressed in this research are those of the authors
and do not necessarily reﬂect the ofﬁcial policy or position of
the Department of the Navy, Department of Defense, Department
of Veterans Affairs, or the U.S. Government. Approved for public




























[906 M.S. Riddle, P. Guerry / V
onﬂict of Interest
Neither of the authors have any relevant conﬂict of interest to
isclose.
eferences
[1] Murray CJ, Vos T, Lozano R, Naghavi M,  Flaxman AD, Michaud C, et al.
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21
regions, 1990–2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 2012;380:2197–223.
[2] Scallan E, Hoekstra RM,  Angulo FJ, Tauxe RV, Widdowson MA,  Roy SL, et al.
Foodborne illness acquired in the United States—major pathogens. Emerg Infect
Dis  2011;17:7–15.
[3] Park MS,  Kim YS, Lee SH, Kim SH, Park KH, Bahk GJ. Estimating the bur-
den of foodborne disease, South Korea, 2008–2012. Foodborne Pathog Dis
2015;12:207–13.
[4] Scharff RL. Economic burden from health losses due to foodborne illness in the
United States. J Food Prot 2012;75:123–31.
[5] Hoffmann S, Batz MB, Morris Jr JG. Annual cost of illness and quality-adjusted
life year losses in the United States due to 14 foodborne pathogens. J Food Prot
2012;75:1292–302.
[6] Havelaar AH, Haagsma JA, Mangen MJ,  Kemmeren JM,  Verhoef LP, Vijgen SM,
et  al. Disease burden of foodborne pathogens in the Netherlands, 2009. Int J
Food Microbiol 2012;156:231–8.
[7] Kubota K, Kasuga F, Iwasaki E, Inagaki S, Sakurai Y, Komatsu M,  et al. Esti-
mating the burden of acute gastroenteritis and foodborne illness caused by
Campylobacter, Salmonella,  and Vibrio parahaemolyticus by using population-
based telephone survey data, Miyagi Prefecture, Japan, 2005 to 2006. J Food
Prot  2011;74:1592–8.
[8] Tam CC, O’Brien SJ, Adak GK, Meakins SM,  Frost JA. Campylobacter coli—an
important foodborne pathogen. J Infect 2003;47:28–32.
[9] Thomas MK,  Murray R, Flockhart L, Pintar K, Pollari F, Fazil A, et al.
Estimates of the burden of foodborne illness in Canada for 30 speciﬁed
pathogens and unspeciﬁed agents, circa 2006. Foodborne Pathog Dis 2013;10:
639–48.
10] Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human campylobacte-
riosis in developing countries. Emerg Infect Dis 2002;8:237–44.
11] Kotloff KL, Nataro JP, Blackwelder WC,  Nasrin D, Farag TH, Panchalingam S,
et  al. Burden and aetiology of diarrhoeal disease in infants and young chil-
dren in developing countries (the Global Enteric Multicenter Study, GEMS): a
prospective, case-control study. Lancet 2013;382:209–22.
12] Platts-Mills JA, Kosek M. Update on the burden of Campylobacter in developing
countries. Curr Opin Infect Dis 2014;27:444–50.
13] Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A, et al. Pathogen-
speciﬁc burdens of community diarrhoea in developing countries: a multisite
birth cohort study (MAL-ED). Lancet Global Health 2015;3:e564–75.
14] Kuwabara S, Yuki N. Axonal Guillain–Barre syndrome: concepts and controver-
sies. Lancet Neurol 2013;12:1180–8.
15] Riddle MS,  Gutierrez RL, Verdu EF, Porter CK. The chronic gastrointesti-
nal  consequences associated with campylobacter. Curr Gastroenterol Rep
2012;14:395–405.
16] Lee G, Pan W,  Penataro Yori P, Paredes Olortegui M,  Tilley D, Gregory
M,  et al. Symptomatic and asymptomatic Campylobacter infections associ-
ated with reduced growth in Peruvian children. PLoS Negl Trop Dis 2013;7:
e2036.
[e 34 (2016) 2903–2906
17] World Health Organization. The global view of campylobacteriosis: Report
of  an expert consultation, Available 〈www.who.int/iris/bitstream/10665/
80751/1/9789241564601 eng.pdf.〉; 2012.
18] Investigators M-EN. The MAL-ED study: a multinational and multidisciplinary
approach to understand the relationship between enteric pathogens, malnu-
trition, gut physiology, physical growth, cognitive development, and immune
responses in infants and children up to 2 years of age in resource-poor envi-
ronments. Clin Infect Dis 2014;59(Suppl 4):S193–206.
19] Blaser MJ,  Berkowitz ID, LaForce FM,  Cravens J, Reller LB, Wang WL.  Campy-
lobacter enteritis: clinical and epidemiologic features. Ann Intern Med
1979;91:179–85.
20] Blaser MJ,  Taylor DN, Echeverria P. Immune response to Campylobacter jejuni
in  a rural community in Thailand. J Infect Dis 1986;153:249–54.
21] Black RE, Levine MM,  Clements ML,  Hughes TP, Blaser MJ. Experimental Campy-
lobacter jejuni infection in humans. J Infect Dis 1988;157:472–9.
22] Tribble DR, Baqar S, Scott DA, Oplinger ML,  Trespalacios F, Rollins D,  et al.
Assessment of the duration of protection in Campylobacter jejuni experimental
infection in humans. Infect Immun  2010;78:1750–9.
23] Parkhill J, Wren BW,  Mungall K, Ketley JM,  Churcher C, Basham D, et al. The
genome sequence of the food-borne pathogen Campylobacter jejuni reveals
hypervariable tracts. Nature 2000;403:665–8.
24] Bacon DJ, Szymanski CM,  Burr DH, Silver RP, Alm RA, Guerry P. A phase variable
capsule is involved in virulence of Campylobacter jejuni 81-176. Mol  Microbiol
2001;40:769–77.
25] Maue AC, Poly F, Guerry P. A capsule conjugate vaccine approach to prevent
diarrheal disease caused by Campylobacter jejuni. Hum Vaccines Immunother
2014;10:1499–504.
26] Liu L, Lai W,  Hu N, Zhang W,  Chen T, Wang F, et al. [Evaluation of immunological
efﬁciency induced by Campylobacter jejuni PEB1 DNA combined with PEB1
protein in mice]. Xi bao yu fen zi mian yi xue za zhi = Chin J Cell Mol  Immunol
2014;30:576–80.
27] Poly F, Serichatalergs O, Kuroiwa J, Pootong P, Mason C, Guerry P,
et  al. Completed Campylobacter jejuni capsule PCR multiplex typing sys-
tem and its application to clinical strains from South East Asia. PLos One
2015;10(12):e0144349.
28] Pike BL, Guerry P, Poly F. Global distribution of Penner serotypes: a systematic
review. PLoS One 2013;8:e67375.
29] Monteiro MA,  Baqar S, Hall ER, Chen Y-H, Porter CK, Bentzel DE, et al. A capsule
polysaccharide conjugate vaccine against diarrheal disease caused by Campy-
lobacter jejuni. Infect Immun 2009;77:1128–36.
30] Tribble DR, Baqar S, Carmolli MP,  Porter C, Pierce KK, Sadigh K, et al. Campylobac-
ter  jejuni strain CG8421: a reﬁned model for the study of Campylobacteriosis
and evaluation of Campylobacter vaccines in human subjects. Clin Infect Dis
2009;49:1512–9.
31] Albert MJ,  Haridas S, Ebenezer M,  Raghupathy R, Khan I. Immunization with a
double-mutant (R192G/L211A) of the heat-labile enterotoxin of Escherichia coli
offers partial protection against Campylobacter jejuni in an adult mouse intesti-
nal colonization model. PLoS One 2015;10:e0142090.
32] Albert MJ, Haridas S, Adler B. Major outer membrane proteins from many
Campylobacter species cross-react with cholera toxin. Clin Vaccine Immunol
2008;15:859–62.
33] Islam A, Raghupathy R, Albert MJ.  Recombinant PorA, the major outer
membrane protein of Campylobacter jejuni,  provides heterologous protec-
tion in an adult mouse intestinal colonization model. Clin Vaccine Immunol
2010;17:1666–71.
34] Albert MJ,  Mustafa AS, Islam A, Haridas S. Oral immunization with cholera toxin
provides protection against Campylobacter jejuni in an adult mouse intestinal
colonization model. mBio 2013;4:e00246–313.
